Key Highlights

  • Nautilus Biotechnology (NASDAQ:NAUT) is scheduled to report third-quarter 2026 results before the market open on Tuesday, October 27, 2026, with a consensus loss of USD 0.16 per share.
  • In the company's release of Tuesday, July 28, 2026, the second quarter showed revenue of about USD 0.2 million, a net loss of about USD 14.5 million and cash and investments of about USD 129.2 million.
  • The company also adjusted its product roadmap alongside the second-quarter results, so the pace of development and the spending needed to reach launch are central to the report.
  • Pre-revenue life science tools names trade on cash runway and milestones, and the Federal Reserve decision on Wednesday, October 28, 2026 affects the cost of capital for the group.

The Setup for a Pre-Revenue Tools Company

Nautilus Biotechnology (NASDAQ:NAUT) is developing a platform for measuring proteins, the molecules that carry out functions in cells, and it is scheduled to report third-quarter results before the open on Tuesday, October 27, 2026. Consensus estimates call for a loss of USD 0.16 per share, and a revenue consensus is not meaningful for a company with almost no sales. In the company's release of Tuesday, July 28, 2026, second-quarter revenue was about USD 0.2 million, the net loss was about USD 14.5 million and cash and investments were about USD 129.2 million. The loss per share beat the estimate. A call usually follows the release, and its exact time has not been confirmed. Results cannot be known in advance.

Why Cash Runway and the Roadmap Set the Share Price

Nautilus Biotechnology (NASDAQ:NAUT) has no commercial product, so the shares reflect confidence in the technology and in the company's ability to fund it. A quarterly net loss of about USD 14.5 million against USD 129.2 million of cash and investments implies a runway of roughly two years, which is simple arithmetic on two published figures and assumes spending stays level. A revised roadmap can extend or shorten that period, because delays raise cumulative cost while a narrower scope lowers it. Early access customers, technical data and launch timing are the milestones that influence valuation. Academic and biopharma budgets, which fund proteomics tools, and the cost of raising equity are the external forces.

Risks and What to Watch

The bull case is a loss at or smaller than USD 0.16 per share, a stable cash balance and concrete technical progress or early customer evidence that supports the revised roadmap. That outcome could lift the shares by a high single-digit or double-digit percentage, because small development-stage stocks move sharply on milestones. The bear case is a wider loss, a further delay or a signal that new funding will be needed sooner, which could cause a decline of similar size. Investors should watch operating expenses, cash and investments, launch timing and any commentary on partners. Nautilus Biotechnology (NASDAQ:NAUT) also faces the Federal Reserve decision on Wednesday, October 28, 2026, after the September increase.

Where Things Stand

The answer is that Nautilus Biotechnology (NASDAQ:NAUT) reports against a USD 0.16 loss consensus, but the result is likely to be judged on cash burn and roadmap progress rather than the loss per share. With about USD 129.2 million in cash at the end of the second quarter, funding is not an immediate issue. The next catalysts are the release before the open on Tuesday, October 27, 2026, the management call that follows and the Federal Reserve decision on Wednesday, October 28, 2026. Consensus figures are estimates, not guarantees, and this is not investment advice.